Joint Bone Spine: Volume 88 (Issue 1 to Issue 6)
Certainly! The “Joint Bone Spine” is a renowned international e-only journal that publishes bimonthly. It specializes in the dissemination of original research and advancements related to disorders of the joints, bones, spine, and broadly, the entire spectrum of rheumatology and rheumatic diseases.
One of the journal’s key strengths is its rigorous peer-review process. Every manuscript submitted undergoes a stringent review by international experts in the field. This ensures that only the highest quality research and information are presented to its readership. It’s important to note that the journal does not promise publication until the editorial board, after comprehensive deliberation, makes its final decision. This meticulous approach guarantees the integrity and credibility of the content published.
However, prospective authors should be aware that the “Joint Bone Spine” has specific delineations regarding its scope. Submissions focused solely on surgical techniques and those emphasizing orthopedic surgery are not considered suitable for this journal.
In terms of accessibility, “Joint Bone Spine” is indexed in leading international databases, making it easy for researchers and medical professionals globally to access the invaluable content. The journal is available on renowned platforms like ScienceDirect and ClinicalKey.
Additionally, for the benefit of French-speaking professionals, select articles from “Joint Bone Spine” may undergo translation and get published in “Revue du Rhumatisme”. This is an editorial choice, and the translated articles in “Revue du Rhumatisme” serve as the official publication for the French Society of Rheumatology (SFR).
In essence, “Joint Bone Spine” stands as a paramount source of knowledge for professionals and researchers in rheumatology, offering them insights, research, and advancements that are pivotal to the field. The journal’s commitment to quality, paired with its international reach, makes it an indispensable resource in the realm of rheumatic diseases.
Volume 88, Issue 1: January 2021
Practical management of patients on anti-TNF therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI)
This supplement was published with institutional funding provided by AbbVie, Amgen, Biogen, Celltrion, Fresenius Kabi, MSD, Mylan, Pfizer, Sandoz and UCB.
Volume 88, Issue 2, Supplement 1, May 2021
Volume 88, Issue 2: March 2021
Practical management of patients on anti-IL17 therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI)
This supplement was published with institutional funding provided by Lilly and Novartis.
Volume 88, Issue 3, Supplement 1, May 2021
Volume 88, Issue 3: May 2021
Practical management of patients on anti-IL6R therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI)
This supplement was published with support from the Club Rhumatismes et Inflammation (CRI).
Volume 88, Issue 4: July 2021
Practical management of patients on hydroxychloroquine
This supplement was produced in partnership with FAI2R, SFR, SNFMI, SFD, and SOFREMIP, under the aegis of CRI.
Volume 88, Issue 5, Supplement 1, December 2021
Reviews
There are no reviews yet.